NASDAQ:AGIO Agios Pharmaceuticals - AGIO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $29.48 +0.29 (+0.99%) (As of 01/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$29.09▼$29.8550-Day Range$26.26▼$31.5252-Week Range$16.75▼$34.76Volume449,597 shsAverage Volume508,075 shsMarket Capitalization$1.62 billionP/E RatioN/ADividend YieldN/APrice Target$53.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Agios Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside80.9% Upside$53.33 Price TargetShort InterestBearish12.68% of Float Sold ShortDividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews Sentiment1.29Based on 3 Articles This WeekInsider TradingSelling Shares$577,000 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($6.53) to ($6.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.15 out of 5 starsMedical Sector490th out of 1,055 stocksPharmaceutical Preparations Industry242nd out of 518 stocks 3.4 Analyst's Opinion Consensus RatingAgios Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $53.33, Agios Pharmaceuticals has a forecasted upside of 80.9% from its current price of $29.48.Amount of Analyst CoverageAgios Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.68% of the float of Agios Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAgios Pharmaceuticals has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.Change versus previous monthShort interest in Agios Pharmaceuticals has recently decreased by 1.18%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAgios Pharmaceuticals does not currently pay a dividend.Dividend GrowthAgios Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAgios Pharmaceuticals has received a 73.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Agios Pharmaceuticals is -0.87. Previous Next 3.5 News and Social Media Coverage News SentimentAgios Pharmaceuticals has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Agios Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest4 people have searched for AGIO on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Agios Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $577,000.00 in company stock.Percentage Held by InsidersOnly 4.48% of the stock of Agios Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($6.53) to ($6.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agios Pharmaceuticals is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agios Pharmaceuticals is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAgios Pharmaceuticals has a P/B Ratio of 1.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Agios Pharmaceuticals (NASDAQ:AGIO) StockAgios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.Read More Receive AGIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AGIO Stock News HeadlinesJanuary 30, 2023 | marketwatch.comCholangiocarcinoma Pipeline Market 2023 : Trends, Industry Size, Share, Emerging Trends, Top Leading Players and Forecast 2028January 22, 2023 | americanbankingnews.comInsider Selling: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Sells 20,000 Shares of StockFebruary 1, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 15, 2023 | finance.yahoo.comShareholders in Agios Pharmaceuticals (NASDAQ:AGIO) are in the red if they invested five years agoJanuary 8, 2023 | finance.yahoo.comAgios Unveils 2023-2026 Value-driving Catalysts Enabling Company’s Vision to Transform Patient Outcomes in Rare DiseasesJanuary 7, 2023 | forbes.comAgios PharmaceuticalsJanuary 3, 2023 | finance.yahoo.comAgios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial OfficerJanuary 3, 2023 | finance.yahoo.comAgios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial OfficerFebruary 1, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.December 22, 2022 | uk.finance.yahoo.comCENTOGENE Reports Second Quarter and First Half 2022 Financial ResultsDecember 21, 2022 | finance.yahoo.comAgios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023December 12, 2022 | seekingalpha.comAgios rare blood disorder drug Pyrukynd sustains benefits in patients in long term dataDecember 11, 2022 | finance.yahoo.comAgios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and ExpositionDecember 10, 2022 | finance.yahoo.comAgios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent α- and β-Thalassemia at 64th ASH Annual Meeting and ExpositionDecember 6, 2022 | finance.yahoo.comAgios Appoints Tsveta Milanova as Chief Commercial OfficerNovember 30, 2022 | finance.yahoo.comAgios to Participate in December Investor ConferenceNovember 22, 2022 | bizjournals.comAlexion's new U.S. head is looking for 'the next generation of medicines to unpack'November 17, 2022 | msn.comBenzinga's Top Ratings Upgrades, Downgrades For November 17, 2022November 17, 2022 | seekingalpha.comAgios Pharmaceuticals upgraded to neutral at Goldman Sachs on Pyrukynd outlookNovember 17, 2022 | msn.comAgios Pharmaceuticals's Return On Capital Employed OverviewNovember 17, 2022 | finance.yahoo.comThe Petri Dish: Moderna touts new booster; MGH spins out diagnostics startupNovember 11, 2022 | finance.yahoo.comEurope Approves Agios Pharma's Mitapivat For Adult Pyruvate Kinase Deficiency PatientsNovember 10, 2022 | finance.yahoo.comPYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult PatientsNovember 9, 2022 | finance.yahoo.comAre Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 34%?November 4, 2022 | seekingalpha.comAgios Pharmaceuticals, Inc. (AGIO) Q3 2022 Earnings Call TranscriptNovember 3, 2022 | finance.yahoo.comAgios Reports Business Highlights and Third Quarter 2022 Financial ResultsNovember 3, 2022 | finance.yahoo.comAgios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 64th ASH Annual Meeting and ExpositionSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AGIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AGIO Company Calendar Last Earnings11/03/2022Today2/01/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGIO CUSIPN/A CIK1439222 Webwww.agios.com Phone(617) 649-8600FaxN/AEmployees390Year FoundedN/APrice Target and Rating Average Stock Price Forecast$53.33 High Stock Price Forecast$96.00 Low Stock Price Forecast$32.00 Forecasted Upside/Downside+80.9%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($6.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$1.60 billion Net MarginsN/A Pretax Margin-3,694.98% Return on Equity-31.40% Return on Assets-28.19% Debt Debt-to-Equity RatioN/A Current Ratio14.65 Quick Ratio14.55 Sales & Book Value Annual Sales$203.20 million Price / Sales7.97 Cash FlowN/A Price / Cash FlowN/A Book Value$23.79 per share Price / Book1.24Miscellaneous Outstanding Shares54,940,000Free Float52,483,000Market Cap$1.62 billion OptionableOptionable Beta1.01 Key ExecutivesBrian M. GoffChief Executive Officer & DirectorCecilia JonesChief Financial OfficerClive PatienceExecutive Vice President-Technical OperationsSarah GheuensChief Medical Officer, Head-Research & DevelopmentTsveta MilanovaChief Commercial OfficerKey CompetitorsPliant TherapeuticsNASDAQ:PLRXArcus BiosciencesNYSE:RCUSRocket PharmaceuticalsNASDAQ:RCKTArvinasNASDAQ:ARVNChinook TherapeuticsNASDAQ:KDNYView All CompetitorsInsiders & InstitutionsInspire Investing LLCBought 1,199 shares on 1/26/2023Ownership: 0.015%David P SchenkeinSold 20,000 sharesTotal: $577,000.00 ($28.85/share)Assenagon Asset Management S.A.Bought 18,839 shares on 1/12/2023Ownership: 0.205%Hennion & Walsh Asset Management Inc.Bought 2,944 shares on 1/12/2023Ownership: 0.042%Bank of New York Mellon CorpBought 20,410 shares on 12/8/2022Ownership: 0.584%View All Insider TransactionsView All Institutional Transactions AGIO Stock - Frequently Asked Questions Should I buy or sell Agios Pharmaceuticals stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AGIO shares. View AGIO analyst ratings or view top-rated stocks. What is Agios Pharmaceuticals' stock price forecast for 2023? 6 equities research analysts have issued twelve-month price targets for Agios Pharmaceuticals' stock. Their AGIO share price forecasts range from $32.00 to $96.00. On average, they predict the company's share price to reach $53.33 in the next twelve months. This suggests a possible upside of 80.9% from the stock's current price. View analysts price targets for AGIO or view top-rated stocks among Wall Street analysts. How have AGIO shares performed in 2023? Agios Pharmaceuticals' stock was trading at $28.08 at the beginning of the year. Since then, AGIO stock has increased by 5.0% and is now trading at $29.48. View the best growth stocks for 2023 here. When is Agios Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our AGIO earnings forecast. How were Agios Pharmaceuticals' earnings last quarter? Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) issued its quarterly earnings data on Thursday, November, 3rd. The biopharmaceutical company reported ($1.49) EPS for the quarter, topping analysts' consensus estimates of ($1.75) by $0.26. The biopharmaceutical company earned $3.52 million during the quarter, compared to analyst estimates of $5.24 million. During the same quarter last year, the firm earned ($1.48) earnings per share. What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO? 11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Agios Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX). What is Agios Pharmaceuticals' stock symbol? Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO." Who are Agios Pharmaceuticals' major shareholders? Agios Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.20%), Hennion & Walsh Asset Management Inc. (0.04%), Inspire Investing LLC (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Carman Alenson, Christopher Bowden, Darrin Miles, David P Schenkein and Theodore James Jr Washburn. View institutional ownership trends. How do I buy shares of Agios Pharmaceuticals? Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Agios Pharmaceuticals' stock price today? One share of AGIO stock can currently be purchased for approximately $29.48. How much money does Agios Pharmaceuticals make? Agios Pharmaceuticals (NASDAQ:AGIO) has a market capitalization of $1.62 billion and generates $203.20 million in revenue each year. The biopharmaceutical company earns $1.60 billion in net income (profit) each year or ($6.65) on an earnings per share basis. How many employees does Agios Pharmaceuticals have? The company employs 390 workers across the globe. How can I contact Agios Pharmaceuticals? Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.agios.com. The biopharmaceutical company can be reached via phone at (617) 649-8600 or via email at investors@agios.com. This page (NASDAQ:AGIO) was last updated on 2/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.